Clorox Shorts Stay Stubborn as Street Lifts Targets After Earnings Beat

CLX has gained 7.4% over the past week to $93.80, outpacing a peer median of 3.8%, yet short sellers have not retreated far enough to suggest the bear case is closing.

Short interest in Clorox is now 8.74% of free float, roughly 10.66 million shares. That is down 4.3% on the week but up 19% over the past month, a net accumulation that persists even after the sharp pre-earnings unwind documented earlier. The one-week reduction masks what is still a materially rebuilt position: from late-September levels near 9 million shares, shorts pushed above 12.5 million in early October, pulled back ahead of the November 2 print, and now sit at an intermediate level that is still well above where they started the autumn. The ORTEX short score, at 55.4, has pulled back from its October 28 peak of 64.6 but remains elevated, consistent with a position that is unwinding rather than collapsing. Borrow conditions offer no friction in either direction: cost to borrow is 0.50%, a touch lower than a week ago, and availability has loosened to 326% of short interest, meaning shares available to lend comfortably exceed those already borrowed. The short score's rank in the 15th percentile of its sector underlines that the remaining position is still more stubborn than average for a household products name. Options positioning is neutral, with the put/call ratio at 0.89, almost exactly on its 20-day average of 0.89, and a z-score near zero. No unusual directional tilt in derivatives.

The Street's response to the earnings print has been a coordinated target lift, with no outright rating upgrades beyond the Evercore ISI move to In-Line that landed Monday. Morgan Stanley raised its target to $94 from $87 while holding Equal-Weight. UBS went to $96 from $91 at Neutral. Wells Fargo moved to $90 from $85 at Equal-Weight. JP Morgan, which carries an Underweight, edged its target up to $86 from $83. The mean consensus target is $98.71, about 5% above the current price, a gap that is narrow enough to suggest the Street collectively views the stock as fairly valued after the rally rather than meaningfully cheap. JP Morgan and Barclays both hold Underweight ratings with targets below where the stock is now trading, so the consensus arithmetic flatters the degree of bearish holdouts. Factor scores reinforce the cautious read: EPS momentum ranks in the 26th percentile on a 30-day basis and the 29th percentile over 90 days, meaning estimate revisions have been soft even as forward earnings recover. The dividend score, at the 88th percentile, remains the most distinctive positive in the factor profile.

Retail attention spiked alongside the earnings event. Wikipedia page views for Clorox hit a z-score of 3.3 against the company's own 90-day average on October 30, the highest attention reading in the recent data window. This dataset is not a leading indicator of the company's financials, but it does reflect an unusual burst of public interest around the print, consistent with the stock's sharp move. Among closer peers, CHD gained 3.95% on the week and CL added 3.74%, while KMB fell 4.25%, making Clorox's 7.4% move the standout in the group. That relative strength has been entirely post-earnings, compressing what had been a wide underperformance gap versus household products peers built up through most of the year.

The index rebalance backdrop, while now implemented, is worth noting as context for the ownership register. In September, Clorox moved from MSCI's large-cap indices into MSCI World Small and MSCI USA Small, a change confirmed at the August 2026 quarterly review with an estimated $890 million of buying into the small-cap indices and roughly $894 million of selling out of MSCI World. That mechanical flow completed at end-August. The top holders as of September 30 remain the large passive managers: Vanguard Capital Management at 7.1%, State Street at 7.0%, and BlackRock at 6.3%. BlackRock filed a 13G/A on October 27 showing its stake at 6.3%, down from a prior disclosed level of 8.1%, consistent with the index deletion reducing passive demand from large-cap trackers.

The next earnings date is November 18. Between now and then, the question for the positioning picture is whether the remaining short base continues to unwind toward pre-October levels or stabilises near current levels, and whether the target-lift cycle from the Street translates into further rating upgrades from the banks still carrying Underweight.